New genes discovered regulating brain metastases in lung cancer
Research from McMaster University has identified new regulators of brain metastases in patients with lung cancer.
Aug 8, 2017
0
2
Research from McMaster University has identified new regulators of brain metastases in patients with lung cancer.
Aug 8, 2017
0
2
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center are helping to make strides in the treatment of metastatic melanoma that has spread to the brain.
Jun 9, 2017
0
1
Rakesh Jain, PhD, Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has discovered a novel mechanism behind the ...
Jun 5, 2017
0
8
Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Compared to the current standard of care crizotinib (Xalkori), the newer ...
Jun 5, 2017
0
1
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have been largely left out of recent treatment progress - those whose disease has spread ...
Jun 5, 2017
0
1
While target therapies directed toward genetic mutations that drive a tumor's growth have significantly improved the outlook for many patients, they have not been as successful in controlling brain metastases in several types ...
May 24, 2017
0
78
Ninety percent of cancer deaths are from cancer spread. Breast cancer patients, for example, typically do not die because cancer returns in their breast, they die because it spreads to other parts of their body. The most ...
Mar 2, 2017
0
15
About 10 percent of lung cancers in the United States and as many as 40 percent in Asia are driven by mutations in the EGFR gene. EGFR targeted treatment advances over the previous decade now result in multiple options for ...
Jan 25, 2017
0
3
Phase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The 50 women treated ...
Jan 11, 2017
0
1
While new targeted treatments developed across the past two decades have led to dramatic survival improvements for women with HER2-positive metastatic breast cancer, University of North Carolina Lineberger Comprehensive Cancer ...
Dec 8, 2016
0
7